In the last 20 years, noninvasive serum biomarkers to identify liver fibrosis in patients with
non-alcoholic fatty liver disease (NAFLD) have been developed, validated against liver …

Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is
rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 …

Background and Aims Liver cirrhosis is often associated with type 2 diabetes (T2D), but
research on treatment of T2D in cirrhotic patients is scarce. We investigated the long-term …

Background The aims of this study were to quantify the histological improvement and its risk
factors in patients with NASH enrolled in the placebo arms of randomized controlled trials …

This narrative review aims to illustrate the notion that nonalcoholic steatohepatitis (NASH),
recently renamed metabolic dysfunction-associated steatohepatitis (MASH), is a systemic …

Background Conflicting evidence regarding the prognosis of lean metabolic dysfunction-
associated steatotic liver disease (MASLD) has raised substantial questions. Aim This study …

Clinical and preclinical studies established that supplementing diets with ω3
polyunsaturated fatty acids (PUFA) can reduce hepatic dysfunction in nonalcoholic …

Background MASLD can manifest as hepatocellular damage, which can result in mild
elevation of aminotransferases. However, in some patients, MASLD presents with …

The bidirectional relationship between type 2 diabetes and (non-alcoholic fatty liver disease)
NAFLD is indicated by the higher prevalence and worse disease course of one condition in …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing
public health issue associated with adverse outcomes such as cirrhosis, malignancy …